Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Gilead Sciences, Inc is a drug manufacturers—general business based in the US. Gilead Sciences shares (GILD) are listed on the NASDAQ and all prices are listed in US Dollars. Gilead Sciences employs 11,800 staff and has a trailing 12-month revenue of around USD$22.2 billion.
|52-week range||USD$60.89 - USD$85.79|
|50-day moving average||USD$66.166|
|200-day moving average||USD$73.3077|
|Wall St. target price||USD$79.08|
|Dividend yield||USD$2.72 (4.37%)|
|Earnings per share (TTM)||USD$3.896|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Gilead Sciences shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4431. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$5.6 billion.
The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$22.2 billion|
|Operating margin TTM||18.8%|
|Gross profit TTM||USD$17.8 billion|
|Return on assets TTM||4.37%|
|Return on equity TTM||-1.4%|
|Market capitalisation||USD$78 billion|
TTM: trailing 12 months
There are currently 16.2 million Gilead Sciences shares held short by investors – that's known as Gilead Sciences's "short interest". This figure is 14.1% down from 18.8 million last month.
There are a few different ways that this level of interest in shorting Gilead Sciences shares can be evaluated.
Gilead Sciences's "short interest ratio" (SIR) is the quantity of Gilead Sciences shares currently shorted divided by the average quantity of Gilead Sciences shares traded daily (recently around 9.7 million). Gilead Sciences's SIR currently stands at 1.67. In other words for every 100,000 Gilead Sciences shares traded daily on the market, roughly 1670 shares are currently held short.
However Gilead Sciences's short interest can also be evaluated against the total number of Gilead Sciences shares, or, against the total number of tradable Gilead Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gilead Sciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Gilead Sciences shares in existence, roughly 10 shares are currently held short) or 0.0129% of the tradable shares (for every 100,000 tradable Gilead Sciences shares, roughly 13 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Gilead Sciences.
Find out more about how you can short Gilead Sciences stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 22.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 08/01/2020) is pretty good – landing it in it in the 30th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 0.53/100
Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 12.97/100
Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 7.65/100
Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.
|Total ESG score||22.15|
|Total ESG percentile||29.8|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||2|
Dividend payout ratio: 65.9% of net profits
Recently Gilead Sciences has paid out, on average, around 65.9% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.37% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 4.37% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $2.72 per share.
Gilead Sciences's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Gilead Sciences's most recent dividend payout was on 29 September 2020. The latest dividend was paid out to all shareholders who bought their shares by 14 September 2020 (the "ex-dividend date").
Gilead Sciences's shares were split on a 2:1 basis on 28 January 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Gilead Sciences shares which in turn could have impacted Gilead Sciences's share price.
Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as $60.89 up to $85.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.5775. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.